Drug Product De-TIL-0255
NX-DeTIL-0255-201
Phase 1 mab terminated
Quick answer
Drug Product De-TIL-0255 for Platinum-resistant Ovarian Cancer is a Phase 1 program (mab) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nurix Therapeutics
- Indication
- Platinum-resistant Ovarian Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated